3.4332

3.63% -0.1468

Puma Biotechnology Inc (PBYI)

Overview News Price History Option Chain Financials Discussions Forecast

Puma Biotechnology Inc stock is traded at $3.4332, with a volume of 517.55K. It is down -3.63% in the last 24 hours and up +23.66% over the past month. Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Previous Close:

$3.58

Open:

$3.53

24h Volume:

517.55K

Relative Volume:

0.98

Market Cap:

$176.47M

Revenue:

$226.63M

Net Income/Loss:

$15.38M

P/E Ratio:

10.73

EPS:

0.32

Net Cash Flow:

$35.61M

1W Performance:

+19.38%

1M Performance:

+23.66%

6M Performance:

+44.96%

1Y Performance:

-41.43%

1-Day Range:

$3.3603

$3.65

1-Week Range:

$2.71

$3.67

52-Week Range:

$2.225

$6.055

Puma Biotechnology Inc Stock (PBYI) Company Profile

Name

Puma Biotechnology Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

(424) 248-6500

Address

10880 WILSHIRE BLVD., LOS ANGELES, CA

Employee

185

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PBYI's Discussions on Twitter

Compare PBYI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBYI Puma Biotechnology Inc	3.43	176.47M	226.63M	15.38M	35.61M	0.32
VRTX Vertex Pharmaceuticals Inc	488.51	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.88	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	635.97	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.49	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	113.00	27.34B	3.30B	-501.07M	1.03B	-2.1146

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy
Jun-25-20	Resumed	BofA/Merrill	Underperform
Oct-08-19	Downgrade	Goldman	Neutral → Sell
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-10-19	Downgrade	Citigroup	Buy → Neutral
Jan-17-19	Initiated	Leerink Partners	Mkt Perform
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-17-18	Initiated	Goldman	Sell
May-11-18	Reiterated	Stifel	Buy
Nov-10-17	Reiterated	Citigroup	Buy
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform
Oct-02-17	Reiterated	Stifel	Buy
Sep-11-17	Reiterated	Credit Suisse	Outperform
Jul-10-17	Resumed	Leerink Partners	Outperform
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform
Mar-02-17	Reiterated	RBC Capital Mkts	Sector Perform

View All

Puma Biotechnology Inc Stock (PBYI) Latest News

02:14 AM

Puma Biotechnology’s (PBYI) Buy Rating Reiterated at HC Wainwright - Defense World

02:14 AM

Mar 02, 2025

Results: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance UK

Mar 02, 2025

Feb 28, 2025

PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates - Yahoo Finance

Feb 28, 2025

Puma Biotechnology: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 28, 2025

GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St

Feb 28, 2025